Clinical Trials Logo
  1. Home
  2. Myalgic Encephalomyelitis
  3. NCT06257420

Rapamycin in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome — ME/CFS  

Myalgic Encephalomyelitis Clinical Trial

Official title:
Rapamycin in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Clinical Trial Summary

The goal of this observational study is to assess the clinical response and the effect of autophagy function in ME/CFS patients before, during and throughout oral low dose sirolimus (rapamycin) therapy. The main questions this study aims to answer are: - Does rapamycin reduce the overall symptom burden of ME/CFS and does it improve the quality of life? - Does rapamycin change mTOR driven autophagy deficits observed in a subset of ME/CFS patients? Participants will be asked to complete a series of questionnaires and quality of life instruments before starting rapamycin therapy prescribed by their physician and throughout their course of treatment. Study blood samples will be collected before starting therapy and throughout the course of treatment to assess serological markers of autophagy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06257420
Study type Observational
Source Simmaron Research Inc.
Contact
Status Enrolling by invitation
Phase
Start date December 11, 2023
Completion date June 11, 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05454683 - Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome N/A
Recruiting NCT05059184 - Long-term Sequelae of COVID-19 (Myalgic Encephalomyelitis): An International Cross-Sectional Study
Recruiting NCT04542161 - Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Phase 2
Terminated NCT01730495 - Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome Phase 2
Completed NCT01156909 - B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome Phase 2
Active, not recruiting NCT05167227 - Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing Illnesses Improve Clinical Care of Patients and Represent a Sustainable Approach Within a Federally Qualified Health Center? N/A
Recruiting NCT05741112 - The Long COVID-19 Wearable Device Study N/A
Completed NCT04301609 - Clinical Trial to Assess the Improvement of Fatigue, Sleep Problems, Anxiety / Depression, Neurovegetatives Alterations and Quality of Life After the Administration of ImmunoVita® in Chronic Fatigue Syndrome Patients N/A
Completed NCT05196529 - Inspiratory Muscle Training in ME/CFS and COVID-19 Survivors N/A
Completed NCT00920777 - Survey and Cognitive Behavior Therapy for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis N/A
Completed NCT04741841 - Effect of Probiotics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) N/A
Enrolling by invitation NCT03254823 - Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Recruiting NCT05236465 - A 3-day Course for CFS/ME N/A
Recruiting NCT04100915 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in ME/CFS
Active, not recruiting NCT05664711 - Effect of Stellate Ganglion Block on ME/CFS Phase 1
Enrolling by invitation NCT05273372 - RESTORE ME -- RCT of Oxaloacetate on Improving Fatigue in ME/CFS N/A
Completed NCT02970240 - Cardiopulmonary Testing in ME/CFS to Improve Diagnostic Accuracy
Terminated NCT01156922 - B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome Phase 2
Enrolling by invitation NCT03409653 - Complex Chronic Diseases Program Data Registry
Completed NCT03613129 - Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Phase 1/Phase 2